• 1
    Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-3796.
  • 2
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer; version I, 2012. Available at: Accessed February 1, 2013.
  • 3
    Dowsett M, Cuzick J, Coates A, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509-518.
  • 4
    Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early breast cancer. J Clin Oncol. 2008;26:556-562.
  • 5
    Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early stage breast cancer patients. J Clin Oncol. 2010;28:4120-4128.
  • 6
    Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125:191-200.
  • 7
    Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529-537.
  • 8
    Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
  • 9
    Agency for Healthcare Research and Quality. Closing the quality gap series: comparative effectiveness of medication adherence interventions. Available at: Accessed February 1, 2013.
  • 10
    Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence [serial online]. Cochrane Database Syst Rev. 2008;(4):CD000011.
  • 11
    Ell K, Vourlekis B, Xie B, et al. Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer. 2009;115:4606-4615.
  • 12
    GoodRx. Available at: Accesses February 1, 2013.
  • 13 2012 Drug finder: search for your prescription drug across all Medicare pt D or Medicare Advantage plans. Available at: Accessed February 1, 2013.
  • 14
    Neugut AI, Subar M, Wilde ET, et al. Association between prescription copayment amount and compliance with adjuvant hormonal therapy in women with early breast cancer. J Clin Oncol. 2011;29:2534-2542.
  • 15
    Riley GF, Warren JL, Harlan LC, Blackwell SA. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare pt D [serial online]. Medicare Medicaid Res Rev. 2011;1:E1-E26.
  • 16
    Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood). 2010;29:1988-1994.
  • 17
    Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-2097.
  • 18
    Fendrick AM, Martin JJ, Weiss AE. Value-based insurance design: more health at any price. Health Serv Res. 2012(1 pt 2);47:404-413.
  • 19
    Ito K, Blinder VS, Elkin EB. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol. 2012;30:1468-1475.
  • 20
    Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy for primary breast cancer. J Clin Oncol. 2003;21:602-606.
  • 21
    Owusu C, Buist DS, Field TS, et al. Predictor of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26:549-555.
  • 22
    DeSantis D, Siegel R, Bandi P, Jemal A. Breast cancer statistics. 2011. CA Cancer J Clin. 2011;61:409-418.
  • 23
    Wolters Kluwer Pharmacy Solutions. Source Pharmaceutical Audit Suite. Available at: Accessed February 1, 2013.
  • 24
    Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early stage breast cancer. Clin Breast Cancer. 2007;7:608-618.
  • 25
    Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized controlled trial at 8.1 years median follow-up. Lancet Oncol. 2011;12:1101-1108.
  • 26
    Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135-1141.
  • 27
    Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011;378:771-784.
  • 28
    National Center for Health Statistics. United States Life Tables, 2006. Available at: Accessed February 1, 2013.
  • 29
    Peasgood T, Ward SE, Brazier J. Health state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010;10:553-566.
  • 30
    Lamerato L, Havstad S, Gandhi SK, Jones D, Nathanson D. The economic burden of breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106:1875-1882.
  • 31
    Hayman JA, Langa KM, Kabeto MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001;19:3219-3225.
  • 32
    US Department of Labor. US Consumer Price Index for medical care for all urban consumers. Available at: Accessed February 1, 2013.
  • 33
    Gold MR, Siegel JE, Russel LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
  • 34
    Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
  • 35
    Dunnwald LK, Rossing MA, Li CK. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients [serial online]. Breast Cancer Res. 2007;9:R6.
  • 36
    Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing. Associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-69.
  • 37
    Meropol NJ, Schrag D, Mulvey TM, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27:3868-3874.
  • 38
    Avalere Health, American Cancer Society Cancer Action Network. Cost sharing for cancer patients in Medicare, 2009. Available at: Accessed February 1, 2013.
  • 39
    Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-2350.
  • 40
    Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans. N Engl J Med. 2008;358:375-383.
  • 41
    Swartz K. Cost-sharing: effect on spending and outcomes. Robert Wood Johnson Foundation Synthesis Project Report No. 20, December 2010. Available at: Accessed February 1, 2013.
  • 42
    Pezzin LE, O'Neil MB, Nattinge AB. The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med. 2009(suppl 2):24:S446-S450.
  • 43
    USA Today, Kaiser Family Foundation, Harvard School of Public Health. National survey of households affected by cancer. Available at: Accessed February 1, 2013.
  • 44
    Kaiser Family Foundation: The Medicare pt D coverage gap: costs and consequences in 2007. Available at: Accessed February 1, 2013.
  • 45
    Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S. Change in drug utilization during a gap in insurance coverage: an examination of the Medicare pt D coverage gap [serial online]. PLoS Med. 2011;8:e1001075.
  • 46
    Braithwaite RS, Rosen AM. Linking cost sharing to value: an unrivaled yet unrealized public health opportunity. Ann Intern Med. 2007;146:602-605.
  • 47
    Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7:861-867.
  • 48
    Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26:w195-w203.
  • 49
    Patient Protection and Affordable Care Act of 2010, Pub L No. 111-148. Available at: Accessed February 1, 2013.
  • 50
    de Souza JA, Ratain MJ, Fendrick AM. Value-based insurance design: aligning incentives, benefits, and evidence in oncology. J Natl Compr Canc Netw. 2012;10:18-23.
  • 51
    Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89-99.
  • 52
    Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117:1261-1268.
  • 53
    Baithwaite RS, Omokaro C, Justice AC, Nucifora K, Roberts MS. Can broader diffusion of value-based insurance design increase benefits from US health care without increasing cost? Evidence from a computer simulation model [serial online]. PLoS Med. 7:e100234, 2010.
  • 54
    Davidoff A, Lopert R, Stuart B, Shaffer T, Lloyd JT, Shoemaker JS. Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes. Value Health. 2012;15:404-411.
  • 55
    Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516-1522.
  • 56
    Murphy CC, Bartholomew LK, Carpentier MY, Bluethman SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134:459-478.
  • 57
    Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early stage breast cancer. J Clin Oncol. 2012;30:936-942.